EAM Investors’s Myriad Genetics MYGN Stock Holding History

EAM Investors’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-69,096	Closed	-$3.18M	–	300
2018 Q3	$3.18M	Buy	+69,096	New	+$3.07M	0.47%	97

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

EAM Investors's MYGN Position: Q4 2018 in Review

EAM Investors sold out of Myriad Genetics (MYGN) in Q4 2018, closing a stake of 69,096 shares — an estimated $3.18M sold.

EAM Investors first reported a position in MYGN in Q3 2018 and held it in 1 quarter. The position peaked at $3.18M in Q3 2018. 264 funds tracked by Wall St. Rank hold MYGN as of Q4 2018.

EAM Investors reported no remaining Myriad Genetics position as of Q4 2018 after selling out during the quarter.
EAM Investors sold 69,096 Myriad Genetics shares in Q4 2018, an estimated $3.18M.
EAM Investors first reported a position in Myriad Genetics in Q3 2018 and held it in 1 quarter.
EAM Investors's Myriad Genetics position peaked at $3.18M in Q3 2018.
264 funds tracked by Wall St. Rank held Myriad Genetics as of Q4 2018.

Based on EAM Investors's 13F filing for Q4 2018, filed 13 Feb 2019.